Login / Signup

Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1).

A Richey SharrettHuzhang MaoVivian T ThieuLaura Fernández LandóMelissa K Thomas
Published in: Journal of the Endocrine Society (2023)
As monotherapy for early T2D, tirzepatide achieved significant improvements in biomarkers of both pancreatic beta-cell function and IS.
Keyphrases
  • type diabetes
  • combination therapy
  • open label
  • cardiovascular disease
  • glycemic control
  • insulin resistance
  • randomized controlled trial
  • metabolic syndrome